Hang Zhou Shi

Researchers are studying myelofibrosis MF, a disease involving abnormal bone marrow fibrosis, stem cell growth, and inflammation, which is difficult to monitor due to invasive biopsy methods. This observational study aims to assess the usefulness and accuracy of two imaging techniques, 18F-FDG PETCT and 18F-FAPI PETMRI, in evaluating systemic fibrosis in MF patients. The study will also explore how these imaging results relate to patients clinical outcomes. Participants diagnosed with primary or secondary myelofibrosis will undergo both 18F-FDG PETCT and 18F-FAPI PETMRI scans. The study design is prospective, observational, self-controlled, and conducted across multiple centers. Imaging, hematologic, cytogenetic, and pathological assessments will be performed within two weeks of each other. Patients must be stable and able to cooperate with the imaging procedures. During the study, participants will be monitored over an average of two years to evaluate the diagnostic performance of 18F-FAPI PETMRI and compare clinical prognoses based on imaging and pathology results. The study will include assessments such as imaging scans and clinical follow-up. Safety and adherence to protocol will be tracked, with informed consent required. The goal is to improve noninvasive monitoring of myelofibrosis progression and treatment effects.

This research aims to evaluate the use of 18F-metafluorobenzylguanidine 18F-MFBG positron emission tomography PET in diagnosing neuroblastoma, a cancer that often expresses norepinephrine transporter NET. The current imaging methods using radioactive iodine-labeled compounds have limitations such as low resolution, long procedures, and difficulty detecting small lesions. This study will look at the safety, image quality, and diagnostic ability of 18F-MFBG, which can be used shortly after injection and shows promise based on preliminary data. Participants will receive a single intravenous dose of 18F-MFBG at 2-5 MBqkg. After 60 minutes, patients will undergo a PETCT or PETMR scan to visualize the tumor. This approach allows for quicker imaging compared to prior methods and aims to better detect neuroblastoma lesions. The study will compare this imaging techniques performance with other images and assess its value for predicting progression-free survival in high-risk patients. During the study, patients will be monitored for diagnostic efficacy over an average of 1.5 years, with secondary outcomes tracked for up to 3-4 years in some cases. Assessments include image quality, tumor burden evaluation, and safety observations. Participants will be involved in the injection and scanning procedures, with follow-up to assess prognosis and imaging performance. The total participation duration varies depending on outcome tracking needs.

This research aims to evaluate how well 18F-metafluorobenzylguanidine 18F-MFBG PET imaging detects and measures tumor burden in patients with pheochromocytoma, a type of tumor that highly expresses the norepinephrine transporter NET. The study addresses limitations of current imaging methods, such as low resolution and long procedure times, by assessing a newer tracer that may provide better image quality and faster results. Patients with suspected or confirmed pheochromocytoma will receive a single intravenous injection of 18F-MFBG at a dose of 5.55 MBqkg. After 60 minutes, participants will undergo a PETCT or PETMR scan to visualize the tumors. This imaging method allows for scanning shortly after injection without special preparation, potentially improving diagnostic processes. During the study, researchers will evaluate the safety of 18F-MFBG, the quality of the images, and how accurately the scans correspond to pathological diagnosis and treatment effects. They will monitor false positive and false negative results over about one year. Participants will be assessed through imaging and clinical follow-up, contributing to understanding the tracers diagnostic value in pheochromocytoma.

Researchers are evaluating the use of 18F-Pentixafor PET imaging to improve the diagnosis, staging, and response evaluation of hematological malignancies such as multiple myeloma, leukemia, and lymphoma. This imaging method targets the CXCR-4 receptor, which is overexpressed in these tumors and is linked to tumor growth and poor prognosis. The study aims to assess how well 18F-Pentixafor PET performs compared to current imaging methods like 18F-FDG PET. Participants will receive a single intravenous injection of 18F-Pentixafor at a dose of 55 MBqkg. After 60 minutes, they will undergo either a PETCT or PETMR scan. This process allows for detailed imaging without special preparation. The study includes patients with suspected or confirmed hematological malignancies and involves only one imaging session per participant. During the study, researchers will monitor diagnostic accuracy and compare 18F-Pentixafor PETs performance with traditional 18F-FDG PET imaging. They will also assess disease activity using the Deauville Score over a period of up to 3-4 years. Participants will be involved in imaging procedures and may undergo biopsies if needed for diagnosis. The study will continue until December 2029, with an average follow-up of about 1.5 years for primary outcome assessment.

Researchers are investigating a new method to assess Adolescent Idiopathic Scoliosis AIS, a common spinal deformity in teenagers. They aim to improve early diagnosis and accurate evaluation of scoliosis progression by using a 3D depth camera, which offers a precise and radiation-free way to measure back surface shape. Traditional methods like trunk rotation angle ATR and Cobb angle rely on X-rays and clinical exams but have limitations such as radiation exposure and lower sensitivity. This study uses the Kinect v2 depth camera to capture detailed 3D images of the back, focusing on measuring the Back Height Difference BHD as a quantitative indicator of spinal deformity. Participants will also have their ATR measured with a Scoliometer and Cobb angle assessed by spinal specialists. Measurements are repeated by different assessors to ensure accuracy, with procedures spaced by five minutes and averages taken. If Cobb angle measurements vary significantly, a senior physician will review them. Participants aged 10 to 18 with diagnosed AIS will undergo these assessments during a short-term inpatient stay of five days. Researchers will collect data on back height difference and trunk rotation angle on the first day of admission. The study monitors participants ability to complete standardized tests without any treatment intervention. This observational study provides a safer, radiation-free alternative to traditional scoliosis assessment methods.

Researchers are evaluating adolescents with idiopathic scoliosis using 3D imaging technology with depth cameras to measure back height difference BHD and angle of trunk rotation ATR. The study aims to compare these measurements before and after conventional treatments such as massage, exercise therapy, and bracing. Statistical analysis will be used to explore the relationship between BHD and ATR and to assess how well BHD detects short-term treatment changes. The study involves a short-term inpatient period of 5 days during which participants receive tailored exercises guided by X-ray mapping, including 3D therapy, breathing techniques, and spinal manipulation known as Tuina. Measurements of BHD and ATR are taken on the first and fifth days of admission to evaluate changes with treatment. Participants will undergo assessments of back height difference and trunk rotation angle at admission and after 5 days of treatment. Researchers will monitor these physical changes to understand treatment effects. The trial is observational and involves adolescents aged 10 to 18 years diagnosed with idiopathic scoliosis. The total participation lasts for the 5-day inpatient treatment period.

Researchers are studying patients with low-risk intermediate-stage nasopharyngeal carcinoma who have responded well to induction chemotherapy and have undetectable levels of plasma EBV-DNA. The trial compares two doses of radiotherapy targeting a specific low-risk area to evaluate their effects on survival, side effects, and quality of life. This phase 3 randomized study aims to find out if lower-dose radiotherapy can maintain treatment success while reducing toxicities related to treatment. Participants receive either reduced-dose radiotherapy 40.2Gy or conventional-dose radiotherapy 49.2Gy to the low-risk target volume called CTV2. Both groups undergo full-course immunotherapy with the PD-1 monoclonal antibody Tislelizumab, administered every three weeks, totaling 12 courses through induction, radiotherapy, and maintenance phases. Induction chemotherapy using a cisplatin-based regimen is given before radiotherapy. Treatment continues until toxicity, progression, withdrawal, or completion of planned courses. During the study, patients will be monitored for progression-free survival and serious adverse events over three years. Secondary measures include metastasis-free survival, relapse-free survival, overall survival, tumor response rates, and quality of life assessments using standard questionnaires over three years. Safety and effectiveness will be evaluated through imaging, laboratory tests, and clinical evaluations. The study enrollment includes adults aged 18 to 75 years, and the follow-up will provide information on long-term outcomes and treatment impact.

Researchers are studying 89Zr-TLX250, a diagnostic imaging agent, to detect clear cell renal cell carcinoma ccRCC in Chinese patients with indeterminate renal masses. This Phase 3, open-label, single-arm study aims to confirm the safety, tolerability, sensitivity, and specificity of 89Zr-TLX250 PETCT imaging. The study supports prior ZIRCON trial data and involves adult patients scheduled for partial or total nephrectomy as part of their standard care. Participants will receive a single intravenous dose of 37 MBq of 89Zr-TLX250 containing 10 mg of girentuximab. Imaging of the abdomen using PETCT will be performed 5 days post-administration, with possible whole-body imaging if widespread disease is suspected. Nephrectomy will occur any time after imaging but within 90 days. Histological analysis of tumor samples will confirm diagnosis. The study includes approximately seven visits over 4 to 6 months. Assessments include baseline exams, PETCT imaging, surgery, and follow-up visits. Imaging and histological data will be centrally analyzed to evaluate diagnostic accuracy. Safety and tolerability will be monitored throughout. The study is expected to last about 12 months with 4 months of follow-up per participant.

Researchers are evaluating BLU-5937, an oral drug, in adults with refractory chronic cough, including unexplained chronic cough, in a randomized, double-blind, placebo-controlled Phase 3 study. The main goal is to assess how BLU-5937 affects 24-hour cough frequency over 24 weeks. This study also monitors safety by tracking adverse events and changes in various health parameters during the treatment period. Participants are randomly assigned to one of three groups BLU-5937 25 mg twice daily, BLU-5937 50 mg twice daily, or a matching placebo taken twice daily. The treatment lasts for 24 weeks, and participants receive their assigned oral medication regularly throughout this time. The study uses a parallel-arm design and includes an extension in China. During the study, participants undergo assessments including cough frequency measurement, vital signs, blood tests for hormones and chemistry, hematology, and ECGs at baseline and Week 24. Researchers also evaluate cough severity and quality of life using questionnaires. Safety is closely monitored by recording adverse events, treatment discontinuations, and laboratory changes. The total participation duration is 24 weeks, with follow-up assessments at specified intervals.

Researchers are conducting a Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rilzabrutinib in adults with active Immunoglobulin G4-related disease IgG4-RD. The study aims to measure the time to the first adjudicated disease flare and assess other important outcomes such as flare-free rates, disease activity control, glucocorticoid use, and safety parameters including adverse events, laboratory tests, and electrocardiograms ECG. Participants will be assigned to one of two groups one receiving rilzabrutinib tablets and the other receiving placebo tablets, both administered orally. The treatment period lasts 52 weeks in a double-blind manner, preceded by a 4 to 6 week screening period. After treatment, there is a 2-week follow-up, with an optional open-label extension lasting up to 108 weeks. The study includes a total of 16 visits during the main period and up to 9 additional visits during the optional extension. During their participation, adults diagnosed with IgG4-RD will undergo repeated imaging procedures such as CT, MRI, PET, or ultrasound to assess disease status. Researchers will monitor disease flares, remission status, glucocorticoid dosage, clinical activity scores, laboratory values, vital signs, and ECG results. Safety monitoring continues up to week 160 to capture treatment-emergent adverse events. Overall, participation lasts up to 60 weeks, with possible extension for those continuing in the optional phase.